Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2977 | SOC plus Placebo IV Wiki | 0.71 |
drug2976 | SOC plus 15mg/kg EB05 IV Wiki | 0.71 |
drug1711 | Intramuscular vaccine Wiki | 0.71 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile. The Phase 3 portion is an event-driven, randomized, observer blinded, placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation compared to placebo. Subjects will be followed for safety and immunogenicity for a period of 12 months after the last vaccination.
Description: Percentage, intensity, and relationship to vaccination of immediate AEs
Measure: Phase 2 portion: Immediate adverse event (AEs) Time: 30 minutesDescription: Percentage, intensity, and relationship to vaccination of solicited local and systemic AEs
Measure: Phase 2 portion: Solicited local and systemic adverse events (AEs) Time: 7 daysDescription: Percentage, intensity, and relationship of unsolicited AEs
Measure: Phase 2 portion: Unsolicited adverse events (AEs) Time: 21 daysDescription: Number of subjects with normal and abnormal clinically significant urine values
Measure: Phase 2 portion: Number of subjects with normal and abnormal clinically significant urine values Time: 3 daysDescription: Number of subjects with normal and abnormal clinically significant haematological values
Measure: Phase 2 portion: Number of subjects with normal and abnormal clinically significant haematological values Time: 3 daysDescription: Number of subjects with normal and abnormal clinically significant biochemical values
Measure: Phase 2 portion: Number of subjects with normal and abnormal clinically significant biochemical values Time: 3 daysDescription: Percentage of subjects with normal and abnormal clinically significant urine values
Measure: Phase 2 portion: Percentage of subjects with normal and abnormal clinically significant urine values Time: 3 daysDescription: Percentage of subjects with normal and abnormal clinically significant haematological values
Measure: Phase 2 portion: Percentage of subjects with normal and abnormal clinically significant haematological values Time: 3 daysDescription: Percentage of subjects with normal and abnormal clinically biochemical values
Measure: Phase 2 portion: Percentage of subjects with normal and abnormal clinically biochemical values Time: 3 daysDescription: Percentage of SAEs, MAAEs, AEs leading to withdrawal, AESIs (including VED), and deaths
Measure: Phase 2 portion: Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths Time: 21 daysDescription: Nab response induced in each Study Population against the SARS-CoV-2 virus
Measure: Phase 2 portion: Neutralizing antibody (Nab assay) response Time: Day 21Description: Nab response induced in each Study Population against the SARS-CoV-2 virus
Measure: Phase 2 portion: Neutralizing antibody (Nab assay) response Time: Day 42Description: Specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 , as measured by IFN-γ ELISpot
Measure: Phase 2 portion:Specific Th1 cell-mediated immunity (CMI) response Time: Day 21Description: Specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 , as measured by IFN-γ ELISpot
Measure: Phase 2 portion:Specific Th1 cell-mediated immunity (CMI) response Time: Day 42Description: First occurrence, in a subject, of laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection
Measure: Phase 3 portion: Laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection Time: 14 daysDescription: Relative percentage of solicited local and systemic AEs following each vaccine administration between the healthy adults (Study Population #1) and the healthy elderly population (Study Population #2, each age strata);
Measure: Phase 2 portion: Solicited local and systemic AEs Time: 7 daysDescription: Percentage of SAEs, MAAEs, AEs leading to withdrawal, AESIs (including VED), and deaths
Measure: Phase 2 portion: Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths Time: Day 43 to 386Description: Percentage, intensity, and relationship to vaccination of immediate AEs
Measure: Phase 3 portion: Immediate adverse event (AEs) Time: 30 minutesDescription: Percentage, intensity, and relationship to vaccination of solicited local and systemic AEs
Measure: Phase 3 portion: Solicited local and systemic AEs Time: 7 daysDescription: Percentage, intensity, and relationship of unsolicited AEs
Measure: Phase 3 portion: Unsolicited adverse events (AEs) Time: 21 daysDescription: Percentage of SAEs, MAAEs, AEs leading to withdrawal, AESIs (including VED), and deaths
Measure: Phase 3 portion: Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths Time: Day 0 to 386Description: Relative neutralizing antibody response between the healthy adults (Study Population #1) and the healthy elderly population (Study Population #2; each age strata) will be analyzed using the Following parameter: Geometric mean tiers (GMT)
Measure: Phase 2 portion: Neutralizing antibody Geometric mean tiers (GMT) response Time: 21 daysDescription: Persistence of the Nab antibody response induced in each Study Population against the SARS-CoV-2 virus
Measure: Phase 2 portion: Neutralizing antibody (Nab assay) response Time: Day 128Description: Persistence of the Nab antibody response induced in each Study Population against the SARS-CoV-2 virus
Measure: Phase 2 portion: Neutralizing antibody (Nab assay) response Time: Day 201Description: Persistence of the Nab antibody response induced in each Study Population against the SARS-CoV-2 virus
Measure: Phase 2 portion: Neutralizing antibody (Nab assay) response Time: Day 386Description: Specific antibody response induced in each Study Population against the SARS-CoV-2 virus will be measured by the total IgG levels
Measure: Phase 2 portion: Specific antibody (IgG) response Time: Day 128Description: Specific antibody response induced in each Study Population against the SARS-CoV-2 virus will be measured by the total IgG levels
Measure: Phase 2 portion: Specific antibody (IgG) response Time: Day 201Description: Specific antibody response induced in each Study Population against the SARS-CoV-2 virus will be measured by the total IgG levels
Measure: Phase 2 portion: Specific antibody (IgG) response Time: Day 386Description: The ratio of neutralizing antibody titers:IgG ELISA antibody titers
Measure: Phase 2 portion: Neutralizing antibody titers: IgG ELISA antibody titers Time: Day 128Description: The ratio of neutralizing antibody titers:IgG ELISA antibody titers
Measure: Phase 2 portion: Neutralizing antibody titers: IgG ELISA antibody titers Time: Day 201Description: The ratio of neutralizing antibody titers:IgG ELISA antibody titers
Measure: Phase 2 portion: Neutralizing antibody titers: IgG ELISA antibody titers Time: Day 386Description: Specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot
Measure: Phase 2 portion: Specific Th1 cell-mediated immunity (CMI) response Time: Day 201Description: Specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot
Measure: Phase 2 portion: Specific Th1 cell-mediated immunity (CMI) response Time: Day 386Description: Specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)
Measure: Phase 2 portion: Specific Th2 cell-mediated immunity (CMI) response Time: Day 21Description: Specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)
Measure: Phase 2 portion: Specific Th2 cell-mediated immunity (CMI) response Time: Day 42Description: Specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)
Measure: Phase 2 portion: Specific Th2 cell-mediated immunity (CMI) response Time: Day 201Description: Specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)
Measure: Phase 2 portion: Specific Th2 cell-mediated immunity (CMI) response Time: Day 386Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)
Measure: Phase 3 portion: Neutralizing antibody Geometric mean titers (GMT) response Time: Day 21Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate
Measure: Phase 3 portion: Neutralizing antibody Seroconversion (SC) rate response Time: Day 21Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)
Measure: Phase 3 portion: Neutralizing antibody Geometric mean fold rise (GMFR) response Time: Day 21Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)
Measure: Phase 3 portion: Neutralizing antibody Geometric mean titers (GMT) response Time: Day 42Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate
Measure: Phase 3 portion: Neutralizing antibody Seroconversion (SC) rate response Time: Day 42Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)
Measure: Phase 3 portion: Neutralizing antibody Geometric mean fold rise (GMFR) response Time: Day 42Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)
Measure: Phase 3 portion: Neutralizing antibody Geometric mean titers (GMT) response Time: Day 128Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate
Measure: Phase 3 portion: Neutralizing antibody Seroconversion (SC) rate response Time: Day 128Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)
Measure: Phase 3 portion: Neutralizing antibody Geometric mean fold rise (GMFR) response Time: Day 128Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)
Measure: Phase 3 portion: Neutralizing antibody Geometric mean fold rise (GMFR) response Time: Day 201Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)
Measure: Phase 3 portion: Neutralizing antibody Geometric mean titers (GMT) Time: Day 201Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate
Measure: Phase 3 portion: Neutralizing antibody Seroconversion (SC) rate response Time: Day 201Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)
Measure: Phase 3 portion: Neutralizing antibody Geometric mean fold rise (GMFR) response Time: Day 386Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)
Measure: Phase 3 portion: Neutralizing antibody Geometric mean titers (GMT) response Time: Day 386Description: In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate
Measure: Phase 3 portion: Neutralizing antibody Seroconversion (SC) rate response Time: Day 386Description: In a subset of subjects, specific antibody response induced in each Study Population against the SARS-CoV-2 virus measured by the total IgG levels
Measure: Phase 3 portion: Specific antibody (IgG) response Time: Day 21Description: In a subset of subjects, specific antibody response induced in each Study Population against the SARS-CoV-2 virus measured by the total IgG levels
Measure: Phase 3 portion: Specific antibody (IgG) response Time: Day 42Description: In a subset of subjects, specific antibody response induced in each Study Population against the SARS-CoV-2 virus measured by the total IgG levels
Measure: Phase 3 portion: Specific antibody (IgG) response Time: Day 128Description: In a subset of subjects, specific antibody response induced in each Study Population against the SARS-CoV-2 virus measured by the total IgG levels
Measure: Phase 3 portion: Specific antibody (IgG) response Time: Day 201Description: In a subset of subjects, specific antibody response induced in each Study Population against the SARS-CoV-2 virus measured by the total IgG levels
Measure: Phase 3 portion: Specific antibody (IgG) response Time: Day 386Description: In a subset of subjects, the ratio of neutralizing antibody titers:IgG ELISA antibody titers
Measure: Phase 3 portion: Neutralizing antibody titers: IgG ELISA antibody titers Time: Day 21Description: In a subset of subjects, the ratio of neutralizing antibody titers:IgG ELISA antibody titers
Measure: Phase 3 portion: Neutralizing antibody titers: IgG ELISA antibody titers Time: Day 42Description: In a subset of subjects, the ratio of neutralizing antibody titers:IgG ELISA antibody titers
Measure: Phase 3 portion: Neutralizing antibody titers: IgG ELISA antibody titers Time: Day 128Description: In a subset of subjects, the ratio of neutralizing antibody titers:IgG ELISA antibody titers
Measure: Phase 3 portion: Neutralizing antibody titers: IgG ELISA antibody titers Time: Day 201Description: In a subset of subjects, the ratio of neutralizing antibody titers:IgG ELISA antibody titers
Measure: Phase 3 portion: Neutralizing antibody titers: IgG ELISA antibody titers Time: Day 386Description: In a subset of subjects, specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot
Measure: Phase 3 portion: Specific Th1 cell-mediated immunity (CMI) response Time: Day 21Description: In a subset of subjects, specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot
Measure: Phase 3 portion: Specific Th1 cell-mediated immunity (CMI) response Time: Day 42Description: In a subset of subjects, specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot
Measure: Phase 3 portion: Specific Th1 cell-mediated immunity (CMI) response Time: Day 201Description: In a subset of subjects, specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot
Measure: Phase 3 portion: Specific Th1 cell-mediated immunity (CMI) response Time: Day 386Description: In a subset of subjects, specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)
Measure: Phase 3 portion: Specific Th2 cell-mediated immunity (CMI) response Time: Day 21Description: In a subset of subjects, specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)
Measure: Phase 3 portion: Specific Th2 cell-mediated immunity (CMI) response Time: Day 42Description: In a subset of subjects, specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)
Measure: Phase 3 portion: Specific Th2 cell-mediated immunity (CMI) response Time: Day 201Description: In a subset of subjects, specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)
Measure: Phase 3 portion: Specific Th2 cell-mediated immunity (CMI) response Time: Day 386Description: In a subset of subjects, specific CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by the percentage of CD4+ T cells expressing functional markers
Measure: Phase 3 portion: Specific cell-mediated immunity (CMI) response Time: Day 0 to 42Description: In a subset of subjects, specific CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by the percentage of CD4+ T cells expressing functional markers
Measure: Phase 3 portion: Specific cell-mediated immunity (CMI) response Time: Day 201 and 386Description: First occurrence, in a subject, of laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection
Measure: Phase 2 portion: Laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection Time: Day 35 to 386Description: Percentage of severe COVID-19 disease
Measure: Phase 2 portion: Severe COVID-19 disease Time: Day 35 to 386Description: Percentage of laboratory-confirmed (confirmed by the ELISA method for the N protein) asymptomatic SARS-CoV-2 infection
Measure: Phase 3 portion: Laboratory-confirmed asymptomatic SARS-CoV-2 infection Time: Day 201Description: Percentage of laboratory-confirmed (confirmed by the ELISA method for the N protein) asymptomatic SARS-CoV-2 infection
Measure: Phase 3 portion: Laboratory-confirmed asymptomatic SARS-CoV-2 infection Time: Day 386Description: Percentage of severe COVID-19 disease
Measure: Phase 3 portion: Severe COVID-19 disease Time: Day 35 to 386Description: Percentage and intensity of COVID-19-related symptoms
Measure: Phase 3 portion: COVID-19-related symptoms Time: 1 yearThis Phase 2 study design will confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile. Subjects will be followed for durability of the immune responses for a period of 12 months after the last vaccination.
Description: Percentage, intensity, and relationship to vaccination of immediate AEs
Measure: Immediate adverse event (AEs) Time: 30 minutesDescription: Percentage, intensity, and relationship to vaccination of solicited local and systemic AEs
Measure: Solicited local and systemic adverse events (AEs) Time: 7 daysDescription: Percentage, intensity, and relationship of unsolicited AEs
Measure: Unsolicited adverse events (AEs) Time: 21 daysDescription: Number of subjects with normal and abnormal clinically significant urine values
Measure: Number of subjects with normal and abnormal clinically significant urine values Time: 3 daysDescription: Percentage of subjects with normal and abnormal clinically significant urine values
Measure: Percentage of subjects with normal and abnormal clinically significant urine values Time: 3 daysDescription: Number of subjects with normal and abnormal clinically significant haematological values
Measure: Number of subjects with normal and abnormal clinically significant haematological values Time: 3 daysDescription: Percentage of subjects with normal and abnormal clinically significant haematological values
Measure: Percentage of subjects with normal and abnormal clinically significant haematological values Time: 3 daysDescription: Number of subjects with normal and abnormal clinically significant biochemical values
Measure: Number of subjects with normal and abnormal clinically significant biochemical values Time: 3 daysDescription: Percentage of subjects with normal and abnormal clinically significant biochemical values
Measure: Percentage of subjects with normal and abnormal clinically significant biochemical values Time: 3 daysDescription: Percentage of SAEs, MAAEs, AEs leading to withdrawal, AESIs (including VED), and deaths
Measure: Serious adverse events (SAEs), Medically attended adverse event (MAAE), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths Time: 21 daysDescription: Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)
Measure: Neutralizing antibody Geometric mean titers (GMT) response Time: Day 21Description: Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)
Measure: Neutralizing antibody Geometric mean titers (GMT) response Time: Day 42Description: Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate
Measure: Neutralizing antibody Seroconversion (SC) rate response Time: Day 21Description: Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate
Measure: Neutralizing antibody Seroconversion (SC) rate response Time: Day 42Description: Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)
Measure: Neutralizing antibody Geometric mean fold rise (GMFR) response Time: Day 21Description: Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)
Measure: Neutralizing antibody Geometric mean fold rise (GMFR) response Time: Day 42Description: Specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot
Measure: Specific Th1 cell-mediated immunity (CMI) response Time: Day 21Description: Specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot
Measure: Specific Th1 cell-mediated immunity (CMI) response Time: Day 42Description: Percentage of SAEs, MAAEs, AEs leading to withdrawal, AESIs (including VED), and deaths
Measure: Serious adverse events (SAEs), Medically attended adverse event (MAAE), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths Time: Day 43 to 386Description: Persistence of Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)
Measure: Neutralizing antibody Geometric mean titers (GMT) response Time: Day 128Description: Persistence of Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)
Measure: Neutralizing antibody Geometric mean titers (GMT) response Time: Day 201Description: Persistence of Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)
Measure: Neutralizing antibody Geometric mean titers (GMT) response Time: Day 386Description: Persistence of Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate
Measure: Neutralizing antibody Seroconversion (SC) rate response Time: Day 128Description: Persistence of Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate
Measure: Neutralizing antibody Seroconversion (SC) rate response Time: Day 201Description: Persistence of Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate
Measure: Neutralizing antibody Seroconversion (SC) rate response Time: Day 386Description: Persistence of Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)
Measure: Neutralizing antibody Geometric mean fold rise (GMFR) response Time: Day 128Description: Persistence of Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)
Measure: Neutralizing antibody Geometric mean fold rise (GMFR) response Time: Day 201Description: Persistence of Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)
Measure: Neutralizing antibody Geometric mean fold rise (GMFR) response Time: Day 386Description: Specific antibody response induced in each Study Population against the SARS-CoV-2 virus measured by the total IgG levels
Measure: Specific antibody (IgG) response Time: Day 21Description: Specific antibody response induced in each Study Population against the SARS-CoV-2 virus measured by the total IgG levels
Measure: Specific antibody (IgG) response Time: Day 42Description: Specific antibody response CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)
Measure: Specific antibody Geometric mean titers (GMT) response Time: Day 128Description: Specific antibody response CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)
Measure: Specific antibody Geometric mean titers (GMT) response Time: Day 201Description: Specific antibody response CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)
Measure: Specific antibody Geometric mean titers (GMT) response Time: Day 386Description: Specific antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate
Measure: Specific antibody Seroconversion (SC) rate response Time: Day 128Description: Specific antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate
Measure: Specific antibody Seroconversion (SC) rate response Time: Day 201Description: Specific antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate
Measure: Specific antibody Seroconversion (SC) rate response Time: Day 386Description: Specific antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)
Measure: Specific antibody Geometric mean fold rise (GMFR) response Time: Day 128Description: Specific antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)
Measure: Specific antibody Geometric mean fold rise (GMFR) response Time: Day 201Description: Specific antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)
Measure: Specific antibody Geometric mean fold rise (GMFR) response Time: Day 386Description: The ratio of neutralizing antibody titers:IgG ELISA antibody titers
Measure: Neutralizing antibody titers: IgG ELISA antibody titers Time: Day 21Description: The ratio of neutralizing antibody titers:IgG ELISA antibody titers
Measure: Neutralizing antibody titers: IgG ELISA antibody titers Time: Day 42Description: The ratio of neutralizing antibody titers:IgG ELISA antibody titers
Measure: Neutralizing antibody titers: IgG ELISA antibody titers Time: Day 128Description: The ratio of neutralizing antibody titers:IgG ELISA antibody titers
Measure: Neutralizing antibody titers: IgG ELISA antibody titers Time: Day 201Description: The ratio of neutralizing antibody titers:IgG ELISA antibody titers
Measure: Neutralizing antibody titers: IgG ELISA antibody titers Time: Day 386Description: Specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot
Measure: Specific Th1 cell-mediated immunity (CMI) response Time: Day 201Description: Specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot
Measure: Specific Th1 cell-mediated immunity (CMI) response Time: Day 386Description: Specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)
Measure: Specific Th2 cell-mediated immunity (CMI) response Time: Day 21Description: Specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)
Measure: Specific Th2 cell-mediated immunity (CMI) response Time: Day 42Description: Specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)
Measure: Specific Th2 cell-mediated immunity (CMI) response Time: Day 201Description: Specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)
Measure: Specific Th2 cell-mediated immunity (CMI) response Time: Day 386Description: Percentage of laboratory-confirmed (confirmed by the ELISA method for the N protein) asymptomatic SARS-CoV-2 infection
Measure: Laboratory-confirmed asymptomatic SARS-CoV-2 infection Time: Day 35 to 386Description: Percentage of severe COVID-19 disease
Measure: Severe COVID-19 disease Time: Day 35 to 386Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports